Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Immutep Ltd ( (AU:IMM) ) has shared an announcement.
Immutep Limited announced the completion of patient enrolment for its EFTISARC-NEO Phase II trial, which evaluates the combination of eftilagimod alpha with radiotherapy and KEYTRUDA® in patients with resectable soft tissue sarcoma. This trial, conducted by the Maria Skłodowska-Curie National Research Institute of Oncology in Poland, has reached its target of 40 patients, showing promising early results with increased tumor hyalinization/fibrosis and a favorable safety profile, potentially enhancing the company’s standing in cancer treatment innovations.
More about Immutep Ltd
Immutep Limited is a clinical-stage biotechnology company focused on developing novel LAG-3 immunotherapies for cancer and autoimmune diseases. With a robust product portfolio, the company is at the forefront of understanding and advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to offer innovative treatment options and maximize shareholder value.
YTD Price Performance: -11.66%
Average Trading Volume: 1,750
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $290.3M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.
